Compare NMFC & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NMFC | PHAT |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 636.6M | 590.6M |
| IPO Year | 2010 | 2019 |
| Metric | NMFC | PHAT |
|---|---|---|
| Price | $7.03 | $5.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 12 |
| Target Price | $8.29 | ★ $19.64 |
| AVG Volume (30 Days) | 638.1K | ★ 1.6M |
| Earning Date | 11-02-2026 | 10-29-2026 |
| Dividend Yield | ★ 14.21% | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $79.63 |
| Revenue Next Year | N/A | $54.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $6.48 | $5.02 |
| 52 Week High | $9.84 | $18.31 |
| Indicator | NMFC | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 56.30 | 33.59 |
| Support Level | $6.82 | $5.02 |
| Resistance Level | $7.30 | $7.72 |
| Average True Range (ATR) | 0.15 | 0.61 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 90.08 | 27.17 |
New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds and mezzanine securities.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.